NasdaqGS:RIGL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases.


Snowflake Analysis

High growth potential with excellent balance sheet.


Similar Companies

Share Price & News

How has Rigel Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RIGL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.8%

RIGL

2.5%

US Biotechs

1.7%

US Market


1 Year Return

-27.5%

RIGL

26.3%

US Biotechs

6.0%

US Market

Return vs Industry: RIGL underperformed the US Biotechs industry which returned 26.7% over the past year.

Return vs Market: RIGL underperformed the US Market which returned 7.4% over the past year.


Shareholder returns

RIGLIndustryMarket
7 Day3.8%2.5%1.7%
30 Day-1.0%7.9%-0.5%
90 Day12.4%25.4%17.8%
1 Year-27.5%-27.5%27.5%26.3%8.2%6.0%
3 Year-25.2%-25.2%34.3%29.8%36.3%27.4%
5 Year-43.3%-43.3%-2.9%-8.5%63.0%45.0%

Price Volatility Vs. Market

How volatile is Rigel Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Rigel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RIGL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RIGL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RIGL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RIGL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RIGL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RIGL is overvalued based on its PB Ratio (4.1x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Rigel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

72.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RIGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: RIGL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RIGL's is expected to become profitable in the next 3 years.

Revenue vs Market: RIGL's revenue (29.3% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: RIGL's revenue (29.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RIGL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Rigel Pharmaceuticals performed over the past 5 years?

2.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RIGL is currently unprofitable.

Growing Profit Margin: RIGL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RIGL is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare RIGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RIGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: RIGL has a negative Return on Equity (-35.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Rigel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: RIGL's short term assets ($116.3M) exceed its short term liabilities ($31.2M).

Long Term Liabilities: RIGL's short term assets ($116.3M) exceed its long term liabilities ($33.7M).


Debt to Equity History and Analysis

Debt Level: RIGL's debt to equity ratio (12.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RIGL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RIGL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RIGL has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 3.5% each year.


Next Steps

Dividend

What is Rigel Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RIGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RIGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RIGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RIGL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RIGL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Raul Rodriguez (59yo)

5.67yrs

Tenure

US$2,562,118

Compensation

Mr. Raul R. Rodriguez has been the Chief Executive Officer of Rigel Pharmaceuticals, Inc., since November 2014 and has been its President since May 2010. Mr. Rodriguez served as Chief Operating Officer at  ...


CEO Compensation Analysis

Compensation vs Market: Raul's total compensation ($USD2.56M) is about average for companies of similar size in the US market ($USD2.13M).

Compensation vs Earnings: Raul's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Raul Rodriguez
President5.67yrsUS$2.56m0.11% $343.6k
Dean Schorno
Executive VP & CFO2.17yrsUS$1.03m0.036% $116.0k
Dolly Vance
Executive VP of Corporate Affairs17.5yrsUS$1.18m0.0044% $14.2k
Esteban Masuda
Executive Vice President of Research3.83yrsUS$796.09k0.015% $47.5k
Wolfgang Dummer
Executive VP & Chief Medical Officer0.75yrUS$779.10kno data
Thomas Raffin
Co-Founderno datano datano data
Nelson Cabatuan
VP of Finance & Interim Principal Accounting Officer2.58yrsno data0.000030% $96.1
Joseph Lasaga
Senior Vice President of Corporate Developmentno datano datano data
Giovanna Matthews
Executive Director of Market Access2.92yrsno datano data
Tarek Sallam
Vice President of Marketingno datano datano data

2.9yrs

Average Tenure

57yo

Average Age

Experienced Management: RIGL's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Raul Rodriguez
President5.67yrsUS$2.56m0.11% $343.6k
Gary Lyons
Independent Chairman of the Board5.67yrsUS$176.75kno data
Walter Moos
Independent Director23.33yrsUS$146.75k0.0013% $4.2k
Keith Katkin
Independent Director5.08yrsUS$143.75kno data
Bradford Goodwin
Independent Director13.5yrsUS$148.75k0.0059% $19.0k
Brian Kotzin
Independent Director2.92yrsUS$160.50kno data
Jane Wasman
Independent Director1.33yrsUS$190.47kno data
Gregory Lapointe
Independent Director2.67yrsUS$148.75kno data

5.4yrs

Average Tenure

64.5yo

Average Age

Experienced Board: RIGL's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Rigel Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rigel Pharmaceuticals, Inc.
  • Ticker: RIGL
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$320.282m
  • Shares outstanding: 168.57m
  • Website: https://www.rigel.com

Number of Employees


Location

  • Rigel Pharmaceuticals, Inc.
  • 1180 Veterans Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RIGLNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2000
RI2ADB (Deutsche Boerse AG)YesCommon StockDEEURNov 2000

Biography

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company’s clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 23:58
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.